Hyperparathyroidism, Secondary
"Hyperparathyroidism, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
| Descriptor ID |
D006962
|
| MeSH Number(s) |
C19.642.355.480
|
| Concept/Terms |
Hyperparathyroidism, Secondary- Hyperparathyroidism, Secondary
- Secondary Hyperparathyroidism
- Hyperparathyroidisms, Secondary
- Secondary Hyperparathyroidisms
|
Below are MeSH descriptors whose meaning is more general than "Hyperparathyroidism, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Hyperparathyroidism, Secondary".
This graph shows the total number of publications written about "Hyperparathyroidism, Secondary" by people in this website by year, and whether "Hyperparathyroidism, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 4 | 2 | 6 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 3 | 1 | 4 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperparathyroidism, Secondary" by people in Profiles.
-
Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
-
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
-
Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment Designation. Clin J Am Soc Nephrol. 2025 Feb 01; 20(2):218-228.
-
Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients. Am J Nephrol. 2026; 57(4):504-513.
-
Serum parathormone, vitamin D and cardiovascular risk factors and markers: A pilot study. Nutr Metab Cardiovasc Dis. 2024 10; 34(10):2298-2304.
-
Parathyroid Allotransplantation: Report of Outcomes in 3 Patients. Transplant Proc. 2024 Jan-Feb; 56(1):173-177.
-
The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism. Ann Surg. 2022 09 01; 276(3):e141-e176.
-
Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043.
-
Celiac Disease and Its Role in the Development of Metabolic Bone Disease. J Clin Densitom. 2020 Apr - Jun; 23(2):190-199.
-
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.